AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXVertex Pharmaceuticals said net product revenues for Q2 2025 increased to $2.9 billion from $2.6 billion in Q2 2024, citing continued strong patient demand for TRIKAFTA/KAFTRIO and early contributions from three ongoing launches.
Key points
AI summaryVertex Pharmaceuticals said net product revenues for Q2 2025 increased to $2.9 billion from $2.6 billion in Q2 2024, citing continued strong patient demand for TRIKAFTA/KAFTRIO and early contributions from three ongoing launches.
The company said total R&D, acquired in-process research and development, and selling, general and administrative expenses for Q2 2025 decreased to $1.4 billion from $5.8 billion in Q2 2024, attributing the decrease to $4.4 billion of acquired in-process research and development expenses incurred from its acquisition of Alpine in May 2024.
Vertex said cash flows from operating activities in the first half of 2025 were $1.9 billion inflow, compared to $2.4 billion outflow in the first half of 2024, with the Alpine acquisition as a principal factor. Cash, cash equivalents and marketable securities increased to $12.0 billion as of June 30, 2025 from $11.2 billion as of December 31, 2024.
The company said the remaining authorized amount under share repurchase programs approved by its board in February 2023 and May 2025 totaled $4.6 billion as of June 30, 2025, and it plans to fund this program with a combination of cash on hand and cash generated from operating activities.
Key figures
Quarter ended June 30, 2025
- Revenue
- $3.0B
- Operating income
- $1.2B
- Net income
- $1.0B
- EPS
- $3.99
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 2025 Net Product Revenues $2.9 billion
Vertex Pharmaceuticals said net product revenues for Q2 2025 increased to $2.9 billion from $2.6 billion in Q2 2024, citing continued strong patient demand for TRIKAFTA/KAFTRIO and early contributions from three ongoing launches.
Source · Based on the MD&A text of the filing
Q2 Total R&D, Acquired In-Process R&D and SG&A $1.4 billion
The company said total R&D, acquired in-process research and development, and selling, general and administrative expenses for Q2 2025 decreased to $1.4 billion from $5.8 billion in Q2 2024, attributing the decrease to $4.4 billion of acquired in-process research and development expenses incurred from its acquisition of Alpine in May 2024.
Source · Based on the MD&A text of the filing
First-Half Operating Cash Flow and Cash Balance
Vertex said cash flows from operating activities in the first half of 2025 were $1.9 billion inflow, compared to $2.4 billion outflow in the first half of 2024, with the Alpine acquisition as a principal factor. Cash, cash equivalents and marketable securities increased to $12.0 billion as of June 30, 2025 from $11.2 billion as of December 31, 2024.
Source · Based on the MD&A text of the filing
Remaining Authorized Share Repurchase Amount $4.6 billion
The company said the remaining authorized amount under share repurchase programs approved by its board in February 2023 and May 2025 totaled $4.6 billion as of June 30, 2025, and it plans to fund this program with a combination of cash on hand and cash generated from operating activities.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…